

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ




پژوهشکده علوم غدد درون ریز و متابولیسم

دانشگاه علوم پزشکی و خدمات بهداشتی درمانی شهید بهشتی

جمهوری اسلامی ایران  
وزارت بهداشت، درمان و آموزش پزشکی

# ژمیران

## ژنوم مرجع ایرانیان



The 14TH International Congress of Endocrine Disorders (ICED14)

Symposium 9: Precision Medicine

**Genome-Wide Association (GWAS) and Polygenic Score (PGS)  
on Type 2 Diabetes in the TCGS**

**Mahdi Akbarzadeh**


**Assistant Professor, Biostatistics (Statistical Genetics)**

Shahid Beheshti University of Medical Sciences (SBMU)

Research Institute for Endocrine Sciences (RIES)

Cellular and Molecular Endocrine Research Center (CMER)

# Outline



# Outline

1 Genetic Association tests

2 Genome-Wide Association (GWAS)


3 Heritability ( $h^2$ )

4 Polygenic Score (PGS)


Defining T2D  
in TCGS

Results of these  
methods in  
Iranians

# T2D is as a multifactorial disorder



# T2D is as a multifactorial disorder




# Preface

## Monogenic disorders




**MODY**





**Simple statistical methods**

## Oligogenic disorders




**Common statistical methods**

## Polygenic disorders



Genome-wide association studies

Whole genome polygenic risk scores



**Modern statistical methods**



# Genetic Association tests



$$Y_i = \beta_0 + \beta_1 X_i + \epsilon_i$$

Labels for the equation components:


- Dependent Variable:  $Y_i$
- Population Y intercept:  $\beta_0$
- Population Slope Coefficient:  $\beta_1$
- Independent Variable:  $X_i$
- Random Error term:  $\epsilon_i$

Groupings:

- Linear component:  $\beta_0 + \beta_1 X_i$
- Random Error component:  $\epsilon_i$


# Genetic Association tests

		Chrom.	DNA sequence	Single Nucleotide Polymorphisms (SNPs)	
				SNP1	SNP2
Person 1	Mat		GTA A C T T G G G A T C T <b>A</b> G A C C A G <b>G</b> A T A G A T	<b>A</b>	<b>A</b>
	Pat		GTA A C T T G G G A T C T <b>A</b> G A C C A G <b>G</b> A T A G A T	<b>A</b>	<b>G</b>
Person 2	Mat		GTA A C T T G G G A T C T <b>A</b> G A C C A G <b>G</b> A T A G A T	<b>A</b>	<b>G</b>
	Pat		GTA A C T T G G G A T C T <b>C</b> G A C C A G <b>G</b> A T A G A T	<b>C</b>	<b>G</b>
Person 3	Mat		GTA A C T T G G G A T C T <b>C</b> G A C C A G <b>G</b> A T A G A T	<b>C</b>	<b>G</b>
	Pat		GTA A C T T G G G A T C T <b>C</b> G A C C A <b>T</b> A T A G A T	<b>C</b>	<b>T</b>



# **Genome-Wide Association Studies (GWAS)**

# Introduction to GWAS



Genome-wide association studies (GWAS) aim to identify associations of genotypes with phenotypes by testing for differences in the allele frequency of genetic variants between individuals who are ancestrally similar but differ phenotypically.


## Genome-wide association studies (GWAS):

- 1- Test hundreds of thousands of genetic variants across many genomes to find those statistically associated with a specific trait or disease.
- 2- Has generated a myriad of robust associations for a range of traits and diseases.
- 3- Number of associated variants is expected to grow steadily as GWAS sample sizes increase.

## 4- GWAS results have a range of applications

- Gaining insight into a phenotype's underlying biology
- Estimating its heritability,
- Calculating genetic correlations
- Making clinical risk predictions
- Informing drug development programmes
- Inferring potential causal relationships between risk factors and health

outcomes.



# Introduction to GWAS

Poor quality data



false positives / negatives

## Steps in QC (plink commands)

1. Sex-check (chr X heterozygosity) (**--check-sex**)
2. Genotyping Call Rate (SNPs missing individuals) (**--geno**)
3. Hardy-Weinberg Equilibrium (**--hwe**)
4. Minor Allele Frequency (**--maf**)
5. Sample Call Rate (individuals missing genotypes) (**--mind**)
6. Proportion of Heterozygosity (**--het**)
7. Relatedness (**--genome**)
8. Population Structure / Stratification (**--cluster-mds-plot**)

*.ped									*.map			
FID	IID	PID	MID	Sex	P	rs1	rs2	rs3	Chr	SNP	GD	BPP
1	1	0	0	2	1	CT	AG	AA	1	rs1	0	870000
2	2	0	0	1	0	CC	AA	AC	1	rs2	0	880000
3	3	0	0	1	1	CC	AA	AC	1	rs3	0	890000

*.fam						*.bed	*.bim										
FID	IID	PID	MID	Sex	P	Contains binary version of the SNP info of the *.ped file. (not in a format readable for humans)						Chr	SNP	GD	BPP	Allele 1	Allele 2
1	1	0	0	2	1							1	rs1	0	870000	C	T
2	2	0	0	1	0							1	rs2	0	880000	A	G
3	3	0	0	1	1							1	rs3	0	890000	A	C

Covariate file				
FID	IID	C1	C2	C3
1	1	0.00812835	0.00606235	-0.000871105
2	2	-0.0600943	0.0318994	-0.0827743
3	3	-0.0431903	0.00133068	-0.000276131


Legend			
FID	Family ID	rs(x)	Alleles per subject per SNP
IID	Individual ID	Chr	Chromosome
PID	Paternal ID	SNP	SNP name
MID	Maternal ID	GD	Genetic distance (morgans)
Sex	Sex of subject	BPP	Base-pair position (bp units)
P	Phenotype	C(x)	Covariates (e.g., Multidimensional Scaling (MDS) components)

Marees et al. *Int J Methods Psychiatr Res.* 2018 Jun; 27(2): e1608.

# Introduction to GWAS: Quantitative Trait

## Linear Regression

$$\hat{Y} = \alpha + \beta X + \varepsilon$$




# Introduction to GWAS: Quantitative Trait

## Linear Regression

$$\hat{Y} = \alpha + \beta X + \varepsilon$$

$\hat{Y}$  = score on phenotype

$X$  = 0, 1 or 2 copies of allele (“G”)



# Introduction to GWAS: Quantitative Trait

## Linear Regression

$$\hat{Y} = \alpha + \beta X + \varepsilon$$


$\hat{Y}$  = score on phenotype

$X$  = 0, 1 or 2 copies of allele (“G”)

$\beta = 0$  no association

$\beta > 0$  G allele associated with higher score on trait



$\beta < 0$  G allele associated with lower score on trait





# Introduction to GWAS: Case-Control

## Logistic Regression




The G allele is associated with disease

Balding. *Nat Rev Genet* (2006)


# Introduction to GWAS: Case-Control

## Logistic Regression



The G allele is associated with disease

Balding. *Nat Rev Genet* (2006)




$$\ln(P/1-P) = \alpha + \beta X + \varepsilon$$

$\beta$  = difference in log odds for cases vs. controls

$e^{(\beta)}$  = difference in odds  
= Odd Ratio (OR)


# Introduction to GWAS: Case-Control

## Logistic Regression



The G allele is associated with disease

Balding. *Nat Rev Genet* (2006)



$$\ln(P/1-P) = \alpha + \beta X + \varepsilon$$


$\beta$  = difference in log odds for cases vs. controls

$e^{(\beta)}$  = difference in odds  
= Odd Ratio (OR)

Allelic effect is an OR:  
OR > 1 increased risk  
OR < 1 decreased risk

# Introduction to GWAS: Relatedness

- Only a few in the total sample = drop



Source: Wikipedia

# Introduction to GWAS: Relatedness


- Only a few in the total sample = drop

- Random Effects Model

$$\hat{Y} = \alpha + \beta X + G + \varepsilon$$

$\beta$  = fixed effect of the allele

$G$  = genetic relationship random effect



Source: Wikipedia

$$\hat{\pi}_{jk} = \frac{1}{m} \sum_i \frac{(x_{ij} - 2p_i)(x_{ik} - 2p_i)}{2p_i(1 - p_i)}$$

# Introduction to GWAS: Relatedness

- Only a few in the total sample = drop

- Random Effects Model


$$\hat{Y} = \alpha + \beta X + G + \varepsilon$$

$\beta$  = fixed effect of the allele

$G$  = genetic relationship random effect

- Genetic Relationship Matrix (GRM)

- Sub-sample of SNPs
- Leave One Chromosome Out (LOCO)



Source: Wikipedia

$$\hat{\pi}_{jk} = \frac{1}{m} \sum_i \frac{(x_{ij} - 2p_i)(x_{ik} - 2p_i)}{2p_i(1 - p_i)}$$

# Introduction to GWAS

## Statistical modeling in GWAS:


1. Linear regression
  - I. Fixed effect model
  - II. Random effect mode with GRM (relatedness adjustment)
2. Logistic regression
  - I. Fixed effect model
  - II. Random effect mode with GRM (relatedness adjustment)




Advanced modeling: Using Machin Learning

# Visualizing the GWAS results

## Manhattan plot



## QQ-plot







What is the

# Polygenic Risk Scores


# Introduction to PRS

- Knowing our risk of developing diseases
- Change diet, lifestyle, or medication use
- But how could you know that you're at a high risk ?



# Introduction to PRS

- A major risk factor for common diseases such as heart disease, cancer, and diabetes is our own genetic makeup.
- New studies show that we can now analyze an individual's genes and actually measure that risk using something called **polygenic risk score**.
- Our genes vary from person to person and it's why we're not all the same, but some of these genetic differences can contribute to our risk of complex diseases.




# Introduction to PRS

- For the most common diseases such as heart disease and T2D, it's often not just one or two of these genetic changes that are important.
- There is many of them, each having a **small effect** on the polygenic risk.

# Introduction to PRS


- For the most common diseases such as heart disease and T2D, it's often not just one or two of these genetic changes that are important.
- There is many of them, each having a **small effect** on the polygenic risk.

**POLY** many **GENIC** to do with **genes** **RISK SCORES** scoring a risk.



# Introduction to PRS

## Training dataset: GWAS



DIAGRAM


[Home](#)  
[About](#)  
[DIAGRAM Publications](#)  
[Data Download](#)

### Welcome to DIAGRAM

We currently provide a list of DIAGRAM publications. Summary data is available for Morris et al (2012): Stage 1 GWAS & Stage 2 Metabochip. Also available are summary statistics for the trans-ethnic T2D GWAS meta-analysis as published in Mahajan et al. (2014). For access to these, please follow the links to the left.


# Polygenic Risk Score :

## The first challenge is “Correlated SNPs”



**DS: Discovery Sample**

# Polygenic Risk Score : Manhattan plot: Clumped SNPs



**DS: Discovery Sample**



# Polygenic Risk Score: The second challenge is: How many SNPs do we need? P+T method (Traditional Method)

The discovery set in this study:

## **Discovery sample:**

180,834 affected individuals and  
1,159,055 controls (48.9% non-  
European descent)  
Effective Sample size: 79,074  
#SNP: 10,454,875

## **In TCGS (target data) after QC:**

#SNP: 555,835  
#common SNPs: 538,505  
(96.88%)


## **After Clumping:**

#SNP: 94,532

## **Pvalue sets**

**S1: 0.00 , 1**  
**S2: 0.00 , 0.5**  
**S3: 0.00 , 0.2**  
**S4: 0.00 , 0.1**  
**S5: 0.00 , 0.05**  
**S6: 0.00 , 0.01**  
**S7: 0.00 , 0.001**  
**S8: 0.00 , 0.0001**  
**S9: 0.00 , 0.000001**  
**S10: 0.00 , 0.00000005**

# Polygenic Risk Score: How many SNPs do we need?



# Polygenic Risk Score: How many SNPs do we need?

PT	Threshold	AUC	N.SNPs
PT10	P<5E-08	0.6454	473
PT9	P<1E-06	0.6495	660
PT8	P<1E-04	0.6574	1528
<b>PT7</b>	<b>P&lt;0.001</b>	<b>0.6632</b>	<b>3026</b>
PT6	P<0.01	0.6621	8439
PT5	P<0.05	0.6549	20120
PT4	P<0.1	0.6527	29861
PT3	P<0.2	0.6503	44054
PT2	P<0.5	0.6442	70489
PT1	P<1	0.6396	94517

# Introduction to PRS



nature genetics

Explore content ▾ About the journal ▾ Publish with us ▾ Subscribe

[nature](#) > [nature genetics](#) > [articles](#) > [article](#)

Article | [Published: 12 May 2022](#)

## Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation

[Anubha Mahajan](#) , [Cassandra N. Spracklen](#), [Weihua Zhang](#), [Maggie C. Y. Ng](#), [Lauren E. Petty](#), [Hidetoshi Kitajima](#), [Grace Z. Yu](#), [Sina Rüeger](#), [Leo Speidel](#), [Young Jin Kim](#), [Momoko Horikoshi](#), [Josep M. Mercader](#), [Daniel Taliun](#), [Sanghoon Moon](#), [Soo-Heon Kwak](#), [Neil R. Robertson](#), [Nigel W. Rayner](#), [Marie Loh](#), [Bong-Jo Kim](#), [Joshua Chiou](#), [Irene Miguel-Escalada](#), [Pietro della Briotta Parolo](#), [Kuang Lin](#), [Fiona Bragg](#), [FinnGen](#), [eMERGE Consortium](#), ... [Andrew P. Morris](#)  [+ Show authors](#)

[Nature Genetics](#) **54**, 560–572 (2022) | [Cite this article](#)

**12k** Accesses | **21** Citations | **366** Altmetric | [Metrics](#)



DIAGRAM  
DIAGRAM

[Home](#)

[About](#)

[DIAGRAM Publications](#)

[Data Download](#)

### Welcome to DIAGRAM

We currently provide a list of DIAGRAM publications. Summary data is available for Morris et al (2012): Stage 1 GWAS & Stage 2 Metabochip. Also available are summary statistics for the trans-ethnic T2D GWAS meta-analysis as published in Mahajan et al. (2014). For access to these, please follow the links to the left.

# Introduction to PRS



**bioRxiv**  
THE PREPRINT SERVER FOR BIOLOGY

New Results


[Follow this preprint](#)

## Leveraging functional genomic annotations and genome coverage to improve polygenic prediction of complex traits within and between ancestries

Zhili Zheng, Shouye Liu, Julia Sidorenko, Loic Yengo, Patrick Turley, Alireza Ani, Rujia Wang, Ilja M. Nolte, Harold Snieder, Lifelines Cohort Study, [Jian Yang](#), [Naomi R Wray](#), Michael E Goddard, Peter M Visscher, [Jian Zeng](#)

doi: <https://doi.org/10.1101/2022.10.12.510418>

This article is a preprint and has not been certified by peer review [what does this mean?].



## Biological Psychiatry

A Journal of Psychiatric Neuroscience and Therapeutics

[Articles](#) [Publish](#) [Multimedia](#) [About](#) [Contact](#)

ARCHIVAL REPORT | VOLUME 90, ISSUE 9, P611-620, NOVEMBER 01, 2021

[Download Full Issue](#)

## A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts

[Guiyan Ni](#) • [Jian Zeng](#) • [Joana A. Revez](#) • ... [Jian Yang](#) • [Peter M. Visscher](#) • [Naomi R. Wray](#) [✉](#)


[Show all authors](#)

Published: May 03, 2021 • DOI: <https://doi.org/10.1016/j.biopsych.2021.04.018>

Calculate LD corrected weights by LDpred, PRSice and SBayesR, and SBayesRC.

# Introduction to PRS


Training dataset: GWAS




Test dataset: PGS

$$\sum_{p\text{-val}} \sum_{SNVs} (\text{allele count})_{\text{test}} \times (\text{effect size})_{\text{training}}$$

# Introduction to PRS



# Introduction to PRS






What is the

# Heritability

# Introduction to Heritability

Heritability ( $h^2$ ) quantifies the degree to which inter-individual differences and resemblance in the population are due to genetic factors.



# Introduction to Heritability

Heritability ( $h^2$ ) quantifies the degree to which inter-individual differences and resemblance in the population are due to genetic factors.

If the value,  $Y$ , of trait (=phenotype) can be modelled as

$$Y = G + E$$

*Nice definition but not very useful  
unless we can observe  $G$ !*

Then  $h^2 = \text{var}(G) / \text{var}(Y)$ , i.e. proportion of trait variance explained by genetic factors.

# Any question?

# Definition of T2D in TCGS *and* Results

# American Diabetes Association (ADA) definition




source: [www.diabetes.org](http://www.diabetes.org)

# Two general types of definition: ADA definition


TLGS Phase	Normal	Prediabetes	T2D	Unclear
Phase 1	6,701	1,062	319	2,812
Phase 2	6,481	1,131	466	2,962
Phase 3	7,224	1,057	596	2,284
Phase 4	6,680	1,976	904	1,819
Phase 5	6,027	2,195	1,142	2,153
Phase 6	5,121	1,837	1,305	3,358
ADA	<b>5,780</b>	4,130	<b>2,167</b>	1

# American Diabetes Association (ADA) definition





# 1000 genome projection: Principal Components



## *Quality control before GWAS (imputed data)*

Imputed data: 61,999,570 (~62M)

Imputation Information > 0.50 → 58,124,808

HWE assumption:  $10e-5$  → 55,223,222

Missing per SNP 0.05 → 49,746,903

MAC 5 & MAF 0.05 → 12,419,966

Remove Duplicate → 12,046,290

Remove Reference allele from Multi-Allelic variants → 10,945,256 (~11M)

## *Quality control before GWAS (imputed data)*

Imputed data: 61,999,570 (~62M) ————

Imputation Information > 0.50 → 58,124,808


HWE assumption:  $10e-5$  → 55,223,222

Missing per SNP 0.05 → 49,746,903


MAC 5 & MAF 0.05 → 12,419,966

Remove Duplicate → 12,046,290



Remove Reference allele from Multi-Allelic variants → 10,945,256 (~11M)




# GWAS Scenarios:




# Manhattan plot of the T2D GWAS (Adjusted for age – sex – 10PCs)



Manhattan plot of the T2D GWAS  
(Adjusted for age – sex – 10PCs)



Manhattan plot of the T2D GWAS adjusted for  
(Adjusted for age + sex + 10PCs + PRS)



# Heritability – T2D

Familial and SNP-based heritability are reported based on two relatedness threshold, 0.025 and 0.05, and adjusted by age, sex, 10 PCs, and with/without BMI.

Without adjusted for BMI


Method		Threshold	Heritability	SE	P-value
Single GRM		0.025	0.391	0.0144	2.56e-3
		0.05	0.280	0.0120	8.72e-3
bigK/smallK	pedigree	0.025	0.367	0.045	3.8e-4
		0.05	0.364	0.0457	2.77e-4
	unrelated	0.025	0.227	0.068	3.8e-4
		0.05	0.232	0.068	2.77e-4

It needs to say that there is 8% - 13% still-missing heritability.

# Polygenic Risk Score (PRS) Analysis



# Polygenic Risk Score (PRS) Analysis



**Total Sample size in each group**



Normal	Prediabetes	T2D
5,741	4,111	2,165

↓

**Unrelated Sample size in each group (*g*rm0.05)**


Normal	Prediabetes	T2D
1,746	1,764	1,228

# Polygenic Risk Score (PRS) Analysis




# Polygenic Risk Score (PRS) Analysis

## T2D vs Control



## PreT2D vs Control



# Interaction effect on T2D

**(BMI × PGS & FH × PGS)**


Body Mass Index (BMI) and Family History (FH)

## Investigating on the interaction (BMI × PGS) and (FH × PGS)


- ✓ **BMI: BMI ≥30, BMI < 30**
- ✓ **FH: Family history of T2D (related to the first degree of individual, GRM based selection)**
- ✓ **A multinomial logistic regression was employed to evaluate the genetic susceptibility risk for T2D within BMI categories.**
- ✓ **The model was adjusted for covariates, including age, sex, PRS, 10PCs, BMI×PRS and FH×PRS.**

# Investigating on the interaction (BMI × PGS)

## T2D vs Normal



## PreT2D vs Normal




**P-value of the interaction term in the model was not statistically significant.**

# Investigating on the interaction (FH × PGS)

## T2D versus Normal people



## PreT2D vs Normal people




**P-value of the interaction term in the model was not statistically significant.**

**Regression to normoglycemia**  
**and**  
**Progression to T2D**  
**among**  
**Prediabetics**



# Regression to normoglycemia and Progression to T2D among Prediabetics

TLGS Phase	Normal	Prediabetes	T2D
ADA	5,780	4,130	2,167



Unrelated Sample size in each group ( $g_{rm}0.05$ )

Normal	Prediabetes	T2D
1,746	1,764	1,228

Followed up for ~10yrs (Phase 3 to Phase6)


# Regression to normoglycemia and Progression to T2D among Prediabetics

Unrelated Sample size in each group (*grm*0.05)

Normal	Prediabetes	T2D
1,746	1,764	1,228




Followed up for ~10yrs (Phase 3 to Phase6)




We followed the prediabetes participants through phase 3 to phase 6


Density plot of PRS comparison between progression and regression groups




95% family-wise confidence level



### Progression vs remained prediabetics



### Regression vs remained prediabetics




# Interaction effect on Progression & Regression (BMI × PGS & FH × PGS)


Body Mass Index (BMI) and Family History (FH)

# Investigating on the interaction (BMI × PGS)

## Progression vs Remained Prediabetic




## Regression vs Remained Prediabetic




**P-value of the interaction term in the model was not statistically significant.**

# Investigating on the interaction (FH × PGS)

## Progression vs Remained Prediabetic



## Regression vs Remained Prediabetic



**P-value of the interaction term in the model was not statistically significant.**

# Conclusion

- I. **I need to add that the AUC of the prediction models by adding PRS were statistically higher than the models with only other covariates. So, adding a PRS to the models as a new risk factor can improve the prediction power.**
- II. **As a result of this study, it is claimed that researchers or clinicians can independently rely on the PRS information, in addition the use of FH and/or BMI information.**



# GEMIRAN team



- Queensland University.
- Oxford University.
- University of Pennsylvania.
- University of Michigan.

**AhTnk you!**

**Mahdi Akbarzadeh**  
**akbarzadeh.ms@gmail.com**

# ThAnk you!

Mahdi Akbarzadeh  
akbarzadeh.ms@gmail.com

# Any Questions?

Mahdi Akbarzadeh  
akbarzadeh.ms@gmail.com